前言教酒菌素类抗生素(Chartreusin又名教霉素)是近年来发现了其在实验动物组织系统内对五种实验动物肿瘤(P388,L1210白血病,B16黑色素瘤等)具有重要的治疗作用,引起了人们的关注。教酒菌素由美国的Leach于1953年首先报道了第一株产生菌为教酒放线菌(Stre-ptomyces chartreus NRRL—2287)。在此发现之后,美国Upjohn公司的各种筛选系统证明了教酒菌素的生物学活性,也曾提交给国际肿瘤研究所和Sloan-Kettering研究所进行抗肿瘤试验,于1956年美国的Calhoun报道了抗细菌作用方面的有限的抗菌谱,此外,没有观察到其抗肿瘤作用。1964年瑞士的Eisenhuth发表了教酒菌素的结构。在此期间,日本、美国、苏联相继发现此类产 Introduction Chartreusin, also known as teicoplanin, has recently been found to have important therapeutic effects on five experimental animal tumors (P388, L1210 leukemia, B16 melanoma, etc.) in experimental animal tissue systems, Aroused people’s attention. Tepicacin was first reported by Leach in the United States in 1953 as Streptomyces chartreus NRRL-2287. After this discovery, the various screening systems of Upjohn Company in the United States have proved the biological activity of pefalin, and also submitted to the International Agency for Research on Cancer and the Sloan-Kettering Institute for anti-tumor test. In 1956, Calhoun The limited antimicrobial spectrum in terms of anti-bacterial effects, furthermore, no anti-tumor effect was observed. In 1964 Eisenhuth from Switzerland published the structure of peugenin. During this period, Japan, the United States, the Soviet Union have found such products